| scholarly article | Q13442814 |
| P356 | DOI | 10.1210/JC.2002-022020 |
| P698 | PubMed publication ID | 12970287 |
| P2093 | author name string | Meunier PJ | |
| Sarkar S | |||
| Lips P | |||
| Boivin G | |||
| Ott SM | |||
| Harper KD | |||
| Pinette KV | |||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cholecalciferol | Q139347 |
| P304 | page(s) | 4199-4205 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women | |
| P478 | volume | 88 |
| Q36527954 | Bone geometry and skeletal fragility |
| Q40229256 | Bone matrix mineralization is preserved during early perimenopausal stage in healthy women: a paired biopsy study |
| Q38066387 | Bone mineralization: from tissue to crystal in normal and pathological contexts |
| Q37756589 | Bone quality and osteoporosis therapy |
| Q38149092 | Bone quality: the determinants of bone strength and fragility. |
| Q38364893 | Bone's Material Constituents and their Contribution to Bone Strength in Health, Disease, and Treatment. |
| Q38221766 | Changes in the degree of mineralization with osteoporosis and its treatment |
| Q46335608 | DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass |
| Q34149279 | Effect of sequential treatments with alendronate, parathyroid hormone (1-34) and raloxifene on cortical bone mass and strength in ovariectomized rats |
| Q45929799 | In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization. |
| Q33996713 | Influence of remodeling on the mineralization of bone tissue. |
| Q34600560 | Mineral changes in osteoporosis: a review |
| Q51196095 | Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization. |
| Q36565785 | Osteoporosis prevention and therapy: preserving and building strength through bone quality |
| Q36606767 | Progressive vertebral deformities despite unchanged bone mineral density in patients with sarcoidosis: a 4-year follow-up study |
| Q37244297 | Prolonged alendronate treatment prevents the decline in serum TGF-β1 levels and reduces cortical bone strength in long-term estrogen deficiency rat model |
| Q43267067 | Raloxifene: a selective estrogen-receptor modulator for postmenopausal osteoporosis - a clinical update on efficacy and safety |
| Q55042739 | Selective estrogen receptor modulators (SERMS). |
| Q36718805 | Structural basis of growth-related gain and age-related loss of bone strength |
| Q46878691 | Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial |
| Q34482507 | Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia). |
| Q34682599 | The degree of bone mineralization is maintained with single intravenous bisphosphonates in aged estrogen-deficient rats and is a strong predictor of bone strength |
| Q37101353 | The effect of the microscopic and nanoscale structure on bone fragility |
| Q84204308 | Thinking inside and outside the envelopes of bone: dedicated to PDD |
| Q35000270 | Variability of tissue mineral density can determine physiological creep of human vertebral cancellous bone. |
Search more.